The abstract is read at the publisher; the summary is JClub's.
In NOG mice bearing subcutaneous NCI-N87 gastric tumors, combined PD-1 blockade plus HER2 targeting controlled tumor growth more than either pembrolizumab or trastuzumab alone.
- Why it matters: Chemotherapy can reshape the tumor microenvironment, so it is unclear which transcriptional effects come specifically from PD-1 and HER2 targeting versus treatment-induced changes.
- What they did: Immunodeficient NOG mice received human PBMCs, then were implanted with NCI-N87 cells and randomized to vehicle, pembrolizumab, trastuzumab, or the combination; bulk RNA sequencing assessed pathway and cell-signature changes.
- The result: Combination therapy was linked to reduced proliferation, EMT, and stromal extracellular-matrix remodelling signatures, with lower expression of extracellular matrix genes (including VCAN, SPARC, POSTN, collagen genes, and FAP) and increased cytotoxic immune-associated signatures.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.